Public health value of fixed-dose combinations in hypertension

Blood Pressure

Volumn 17, Issue SUPPL. 1, 2008, Pages 5-14

  Ruilope, Luis M ^a   Burnier, Michel ^b   Muszbek, Noemi ^c   Brown, Ruth E ^c   Keskinaslan, Abdulkadir ^d   Ferber, Philippe ^d   Harms, Günter ^d  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Compliance; Fixed dose combination; Health economics; Hypertension; Persistence; Reimbursement

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE BESYLATE PLUS BENAZEPRIL; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LISINOPRIL; RENIN INHIBITOR; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIET THERAPY; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INFORMATION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; HEALTH CARE COST; HEALTH CARE POLICY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK REDUCTION; COST OF ILLNESS; DRUG COMBINATION; ECONOMICS; REIMBURSEMENT;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HUMANS; HYPERTENSION; PUBLIC HEALTH; TREATMENT OUTCOME; COST OF ILLNESS; DRUG COMBINATIONS; DRUG COSTS; INSURANCE, HEALTH, REIMBURSEMENT; PATIENT COMPLIANCE;

EID: 74249098472     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020802030186     Document Type: Article

References (62)

1. Corren, J. (2005) Evaluation and treatment of asthma: An overview. 11:14, pp. S408-S415.
2. Leichter, S. B. and Thomas, S. (2003) Combination medications in diabetes care: An opportunity that merits more attention. 21, pp. 175-178.
3. Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. 360, pp. 1903-1913.
4. Wolf-Maier, K., Cooper, R. S., Kramer, H., Banegas, J. R., Giampaoli, S. Joffres, M. R. et al. (2004) Hypertension treatment and control in five European countries, Canada, and the United States. 43, pp. 10-17.
5. Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K. and He, J. (2005) Global burden of hypertension: Analysis of worldwide data. 365, pp. 217-223.
6. Wolf-Maier, K., Cooper, R. S., Banegas, J. R., Giampaoli, S., Hense, H-W. Joffres, M. et al. (2003) Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. 289, pp. 2363-2369.
7. Ezzati, M., Lopez, A. D., Rodgers, A., Hoom, S. Vander, Murray, C. J. L. and the Comparative Risk Assessment Collaborating Group (2002) Selected major risk factors and global and regional burden of disease. 360, pp. 1347-1360.
8. World Health Organizationp. 83.
9. Mullins, C. D., Sikirica, M., Seneviratne, V., Ahn, J. and Akras, K. S. (2004) Comparisons of hypertension-related costs from multinational clinical studies. 22, pp. 1001-1014.
10. Chockalingam, A., Campbell, N. R. and Fodor, J. G. (2006) Worldwide epidemic of hypertension. 22, pp. 553-555.
11. Neal, B., MacMahon, S., Chapman, N. and Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. 356, pp. 1955-1964.
12. Klungel, O. H., Kaplan, R. C., Heckbert, S. R., Smith, N. L., Lemaitre, R. N. Longstreth Jr., W. T. et al. (2000) Control of BP and risk of stroke among pharmacologically treated hypertensive patients. 31, pp. 420-424.
13. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D. Julius, S. et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. 351, pp. 1755-1762.
14. ESH-ESC Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension (ESH 2003). 21, pp. 1011-1053.
15. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. Izzo Jr., J. I. et al. (2003) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.289, pp. 2560-2572.
16. Jamerson, K. A., Nwose, O., Jean-Louis, L., Schofield, L., Purkayastha, D. and Baron, M. (2004) Initial angiotensin-converting enzyme inhibitor/ calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. 17, pp. 495-501.
17. Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R. Grimm, R. H. et al. (2002) Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). 4, pp. 393-404.
18. Julius, S., Kjeldsen, S. E., Brunner, H., Hansson, L., Platt, F. Ekman, S. et al. (2003) VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. 16, pp. 544-548.
19. Walley, T., Duggan, A. K., Haycox, A. R. and Niziol, C. J. (2003) Treatment for newly diagnosed hypertension: Patterns of prescribing and antihypertensive effectiveness in the UK. 96, pp. 525-531.
20. Lloyd, A., Schmieder, C. and Marchant, N. (2003) Financial and health costs of uncontrolled blood pressure in the United Kingdom. 21, pp. 33-41.
21. Flack, J. M., Casciano, R., Casciano, J., Doyle, J., Arikian, S. Tang, S. et al. (2002) Cardiovascular disease costs associated with uncontrolled hypertension. 15, pp. 28-36.
22. Esposti, L. Degli and Valpiani, G. (2004) Pharmacoeconomic burden of undertreating hypertension. 22, pp. 907-928.
23. Black, H. R., Elliott, W. J., Grandits, G., Grambsch, P., Lucente, T. White, W. B. et al. (2003) Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. 289, pp. 2073-2082.
24. Burnier, M. (2006) Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. 19, pp. 1190-1196.
25. World Health Organization (WHO) (2003)
26. Berger, M. L., Bingefors, K. Hedblom, E. C. et al. (2003)
27. Sturkenboom, M. C. J. M., Picelli, G., Dieleman, J. P., Mozaffari, E., Pompen, M. and van der Lei, J. (2005) Patient adherence and persistence with antihypertensive therapy: One-versus two-pill combinations. 23, p. S326.
28. DiMatteo, M. R., Giordani, P. J., Lepper, H. S. and Croghan, T. W. (2002) Patient adherence and medical treatment outcomes: A meta-analysis. 40, pp. 794-811.
29. Dezii, C. M. (2000) Medication noncompliance: What is the problem?. 9:9, pp. S7-S12.
30. Taylor, A. A. and Shoheiber, O. (2003) Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. 9, pp. 324-332.
31. Davis, T. C. and Wolf, M. S. (2004) Health literacy: Implications for family medicine. 36, pp. 595-598.
32. Caro, J. J., Speckman, J. L., Salas, M., Raggio, G. and Jackson, J. D. (1999) Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. 160, pp. 41-46.
33. Hughes, D. and McGuire, A. (1998) The direct costs to the NHS of discontinuing and swtching prescriptions for hypertension. 12, pp. 533-537.
34. Osterberg, L. and Blaschke, T. (2005) Adherence to medication. 353, pp. 487-497.
35. Halpern, M. T., Vincze, G., Stewart, W. F. and Khan, Z. M. (2006) Persistence with hypertension therapy and long-term cardiovascular outcomes. 24, pp. S182-S183.
36. Breekveldt-Postma, N. S., Siiskonen, S. J. Beest, F. J. A. Penning-Van et al. (2006) Non-persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. 9, p. A339.
37. Granger, B. B., Swedberg, K., Ekman, I., Granger, C. B., Olofsson, B. McMurray, J. J. et al. (2005) Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomised, controlled trial. 366, pp. 2005-2011.
38. Cleemput, I., Kesteloot, K. and DeGeest, S. (2002) A review of the literature on the economics of non-complicance. Room for methodological improvement. 59, pp. 65-94.
39. McCombs, J. S., Nichol, M. B., Newman, C. M. and Sclar, D. A. (1994) The costs of interrupting antihypertensive drug therapy in a Medicaid population. 32, pp. 214-226.
40. Sokol, M. C., McGuigan, K. A., Verbrugge, R. R. and Epstein, R. S. (2005) Impact of medication adherence on hospitalization risk and healthcare cost. 43, pp. 521-530.
41. Levy, G., Zamacona, M. K. and Jusko, W. J. (2000) Developing compliance instructions for drug labeling. 68, pp. 586-591.
42. Rizzo, J. A., Abbott 3rd., T. A. and Pashko, S. (1996) Labour productivity effects of prescribed medicines for chronically ill workers. 5, pp. 249-265.
43. Jamerson, K. A., Bakris, G. L., Wun, C. C., Dahlof, B., Lefkowitz, M. Manfreda, S. et al. (2004) Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. 17, pp. 793-801.
44. Jamerson, K., Bakris, G. L., Dahlof, B., Pitt, B., Velazquez, E. Gupte, J. et al. (2007) ACCOMPLISH Investigators. Exceptional early blood pressure control rates: The ACCOMPLISH trial. 16, pp. 80-86.
45. Ruilope, L. M., Malacco, E., Khder, Y., Kandra, A., Bonner, G. and Heintz, D. (2005) Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study. 27, pp. 578-587.
46. Andreadis, E. A., Tsourous, G. I., Marakomichelakis, G. E., Katsanou, P. M., Fotia, M. E., Vassilopoulos, C. V. and Diamantopoulos, E. J. (2005) High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. 19, pp. 491-496.
47. Neutel, J. and Smith, D. H. (2003) Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: Meta-analysis of a clinical database. 5, pp. 58-63.
48. Wanovich, R., Kerrish, P., Gerbino and Shoheiber, O. (2004) Compliance patterns of patients treated with two separate antihypertensive agents versus fixed-dose combination therapy. 17, p. 223A.
49. Dickson, M. and Plauschinat, C. A. (2005) Antihypertensive therapy compliance and total cost of care in a Medicaid population: Fixed-dose combination vs free-combination treatment. 62, p. P71E.
50. Hilleman, D. E., Reyes, A. P., Wurdeman, R. L. and Faulkner, M. (2001) Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose comfobination of amlodipine/benazepril in patients with moderate-to-severe hypertension. 15, pp. 559-565.
51. Kountz, D. S. (1997) Cost containment for treating hypertension in African Americans: Impact of a combined ACE inhibitor-calcium channel blocker. 89, pp. 457-460.
52. Dezii, C. M. (2000) A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. 9, pp. S2-S6.
53. Jackson, K., Brixner, D. Oderda, G. et al. (2006) Persistence of fixed versus free combination therapy with valsartan and HCTZ for patients with hypertension. 9, p. A363.
54. Drummond, M. and Jonsson, B. (2003) Moving beyond the drug budget silo mentality in Europe. 6, pp. S74-S77.
55. Wertheimer, A., Santella, T. M., Finestone, A. J. and Levy, R. (2006)
56. Kalo, Z., Muszbek, N., Bodrogi, J. and Bidlo, J. (2006) Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. 89, pp. 401-412.
57. Lopez-Casasnovas, G. and Puig-Junoy, J. (2000) Review of the literature on reference pricing. 54, pp. 87-123.
58. Atella, V., Peracchi, F., Depalo, D. and Rossetti, C. (2006) Drug compliance, co-payment and health outcomes: Evidence from a panel of Italian patients. 15, pp. 875-892.
59. Andersson, K., Petzold, M. G., Sonesson, C., Lonnroth, K. and Caristen, A. (2006) Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. 79, pp. 231-243.
60. Kanavos, P. and Reinhardt, U. (2003) Reference pricing for drugs: Is it compatible with US health care?. 22, pp. 16-30.
61. Koopmanschap, M. A. and Rutten, F. F. H. (2003) The drug budget silo mentality: The Dutch case. 6, pp. S46-S51.
62. Puig-Junoy, J. (2004) Incentives and pharmaceutical reimbursement reforms in Spain. 67, pp. 149-165.